Literature DB >> 20004532

Tumor volume reduction rate measured by magnetic resonance volumetry correlated with pathologic tumor response of preoperative chemoradiotherapy for rectal cancer.

Seung-Gu Yeo1, Dae Yong Kim, Tae Hyun Kim, Kyung Hae Jung, Yong Sang Hong, Hee Jin Chang, Ji Won Park, Seok-Byung Lim, Hyo Seong Choi, Seung-Yong Jeong.   

Abstract

PURPOSE: To determine whether the tumor volume reduction rate (TVRR) measured using three-dimensional region-of-interest magnetic resonance volumetry correlates with the pathologic tumor response after preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer. METHODS AND MATERIALS: The study included 405 patients with locally advanced rectal cancer (cT3-T4) who had undergone preoperative CRT and radical proctectomy. The tumor volume was measured using three-dimensional region-of-interest magnetic resonance volumetry before and after CRT but before surgery. We analyzed the correlation between the TVRR and the pathologic tumor response in terms of downstaging and tumor regression grade (TRG). Downstaging was defined as ypStage 0-I (ypT0-T2N0M0), and the TRG proposed by Dworak et al. was used.
RESULTS: The mean TVRR was 65.0% +/- 22.3%. Downstaging and complete regression occurred in 167 (41.2%) and 58 (14.3%) patients, respectively. The TVRRs according to ypT classification (ypT0-T2 vs. ypT3-T4), ypN classification (ypN0 vs. ypN1-N2), downstaging (ypStage 0-I vs. ypStage II-III), good regression (TRG 3-4 vs. TRG 1-2), and complete regression (TRG 4 vs. TRG 1-3) were all significantly different (p <.05). When the TVRR was categorized into three groups (<60%, 60-80%, and >80%), the rates of ypT0-T2, ypN0, downstaging, and good regression were all significantly greater for patients with a TVRR of >or=60%, as was the complete regression rate for patients with a TVRR >80% (p <.05).
CONCLUSION: The TVRR measured using three-dimensional region-of-interest magnetic resonance volumetry correlated significantly with the pathologic tumor response in terms of downstaging and TRG after preoperative CRT for locally advanced rectal cancer. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20004532     DOI: 10.1016/j.ijrobp.2009.07.1682

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

Review 1.  Multidisciplinary management in rectal cancer.

Authors:  Asunción Hervás Morón; María Luisa García de Paredes; Eduardo Lobo Martínez
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

Review 2.  How Should Imaging Direct/Orient Management of Rectal Cancer?

Authors:  Jemma Bhoday; Svetlana Balyasnikova; Anita Wale; Gina Brown
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

3.  Endoscopic evaluation of clinical response after preoperative chemoradiotherapy for lower rectal cancer: the significance of endoscopic complete response.

Authors:  Atsushi Ogura; Akiko Chino; Tsuyoshi Konishi; Takashi Akiyoshi; Teruhito Kishihara; Yoshiro Tamegai; Masashi Ueno; Masahiro Igarashi
Journal:  Int J Colorectal Dis       Date:  2015-01-09       Impact factor: 2.571

Review 4.  Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review.

Authors:  Byong Chul Yoo; Seung-Gu Yeo
Journal:  EPMA J       Date:  2017-03-03       Impact factor: 6.543

5.  MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Authors:  T Seierstad; K H Hole; K K Grøholt; S Dueland; A H Ree; K Flatmark; K R Redalen
Journal:  Br J Radiol       Date:  2015-04-22       Impact factor: 3.039

6.  Endometrial Cancer: Combined MR Volumetry and Diffusion-weighted Imaging for Assessment of Myometrial and Lymphovascular Invasion and Tumor Grade.

Authors:  Stephanie Nougaret; Caroline Reinhold; Shaza S Alsharif; Helen Addley; Jocelyne Arceneau; Nicolas Molinari; Boris Guiu; Evis Sala
Journal:  Radiology       Date:  2015-04-30       Impact factor: 11.105

7.  Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective study.

Authors:  Jian Xiao; Yuting Tan; Wenyun Li; Jiaying Gong; Zhiyang Zhou; Yan Huang; Jian Zheng; Yanhong Deng; Lei Wang; Junsheng Peng; Donglin Ren; Ping Lan; Jianping Wang
Journal:  Oncol Lett       Date:  2015-04-07       Impact factor: 2.967

8.  Magnetic resonance-based pelvimetry and tumor volumetry can predict surgical difficulty and oncologic outcome in locally advanced mid-low rectal cancer.

Authors:  Gulsen Atasoy; Naciye Cigdem Arslan; Funda Dinc Elibol; Ozgul Sagol; Funda Obuz; Selman Sokmen
Journal:  Surg Today       Date:  2018-06-30       Impact factor: 2.549

9.  Morphologic predictors of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  Chongda Zhang; Feng Ye; Yuan Liu; Han Ouyang; Xinming Zhao; Hongmei Zhang
Journal:  Oncotarget       Date:  2017-12-19

10.  Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma.

Authors:  Zhiling Zhang; Longbin Xiong; Zeshen Wu; Huiming Liu; Kang Ning; Yulu Peng; Chunping Yu; Ya Ding; Desheng Weng; Jianchuan Xia; Lijuan Jiang; Shengjie Guo; Hui Han; Fangjian Zhou; Pei Dong
Journal:  Transl Androl Urol       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.